Neurocrine (NBIX) CCO Eric Benevich Receives PRSUs; 3,386 Withheld

What Happened

• Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences (NBIX), had performance restricted stock units (PRSUs) vest on September 11, 2026. As a result, 6,275 shares were issued to him (reported as an award/acquisition at $0.00 per share).
• To satisfy tax withholding obligations, 3,386 of those vested shares were withheld by the company; the withheld shares are reported at $156.22 per share, totaling $528,961. No open‑market sale of shares occurred.

Key Details

• Transaction date: September 11, 2026 (reported on Form 4 filed September 15, 2026).
• Awarded/Acquired: 6,275 shares (Code A) at $0.00 acquisition price.
• Withheld/Disposed: 3,386 shares (Code F) at $156.22 per share; total = $528,961.
• Footnotes: F1 — PRSUs vested after certification of performance on Sept 11, 2026. F2 — Shares were withheld by the issuer to satisfy tax withholding; no shares were sold.
• Shares owned after the transaction: not specified in the provided filing.
• Timeliness: The Form 4 was filed 4 days after the transaction date; this appears outside the standard 2-business-day window for timely Form 4 filings.

Context

• This was a routine equity award vesting event, not an open-market purchase or sale. Tax-withholding via share retention is common when restricted stock or PRSUs vest and does not necessarily indicate trading intent.
• For retail investors, award vesting increases insider ownership on paper but the withheld shares reduce net new shares received. The withholding is administrative and should not be interpreted as a directional insider trade.